Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: A meta-analysis

Clicks: 11
ID: 318029
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #40 of 51 articles by views in jnci cancer spectrum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: : Novel agents targeting immune checkpoints are under development to overcome resistance to PD-1/PD-L1 and CTLA-4 blockade. Incidences of immune-related adverse events (irAEs) and toxicity profiles of novel agents remain unelucidated. METHODS: : We searched PubMed/MEDLINE, EMBASE, and Web of Science for clinical trials evaluating agents targeting co-inhibitory (B7-H3, CD47, TIGIT, LAG-3, and TIM-3) or co-stimulatory checkpoints (OX40, 4-1BB, CD27, ICOS, GITR, CD70, and CD40) in solid tumors. Incidences of any-grade and grade 3 to 5 (G3-5) treatment-related AEs (trAEs) and irAEs were extracted from phase 2 and 3 trials, and phase 1/2 trials with safety information reported at the recommended phase 2 dose. Odds ratios (ORs) from two-arm studies evaluating the addition of LAG-3 or TIGIT blockade to control-arm therapy were pooled, and AE incidences across immunotherapy subtypes were reported using a random-effects meta-analysis. RESULTS: : A systematic review identified 27 clinical trials comprising 3,946 patients. The addition of LAG-3 blockade increased G3-5 trAEs (OR 1.79, 95% confidence interval [CI]: 1.26-2.54, p = 0.001), adrenal insufficiency (G3-5: OR 8.43, 95%CI: 1.04 to 68.37, p = 0.046; any-grade: OR 4.81, 95%CI: 1.81-12.78, p = 0.002) and any-grade arthralgia (OR 2.07, 95%CI: 1.29-3.30, p = 0.002). Adding TIGIT blockade increased any-grade rash (OR 2.32, 95%CI: 1.01 to 5.34, p = 0.048). Meta-analyses revealed varying irAE patterns: G5 trAEs (0.9-2.9%), G3-5 pneumonitis (0.5-5.5%, highest in TIM-3), G3-5 colitis (0.2 to 5.4%, highest in LAG-3), G3-5 hepatitis (1.5-5.5%, highest in TIM-3), G3-5 adrenal insufficiency (1.7 to 8.4%, highest in TIGIT). CONCLUSIONS: : This study highlights the distinct toxicity profiles of novel immunotherapy agents, providing essential safety data to support clinicians as these therapies approach approval.
Reference Key
openalex_W7165397457 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yu Fujiwara, Yui Okamura, Mrinalini Ramesh, Yasmin Fakhari Tehrani, Riona Aburaki, Toshiaki Takahashi, Manmeet S Ahluwalia, Sarbajit Mukherjee
Journal jnci cancer spectrum
Year 2026
DOI
10.1093/jncics/pkag066
URL
https://doi.org/10.1093/jncics/pkag066
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.